Plasmablastic lymphoma was initially described as a variant of diffuse large B-cell lymphoma (DLBCL) involving the oral cavity of HIV+ patients and characterized by immunoblastic morphology and a plasma cell phenotype. However, other lymphomas may exhibit similar morphologic and immunophenotypic features. To determine the significance of plasmablastic differentiation in DLBCL and examine the heterogeneity of lymphomas with these characteristics, we examined 50 DLBCLs with low/absent CD20/CD79a and an immunophenotype indicative of terminal B-cell differentiation (MUM1/CD38/CD138/EMA-positive). We were able to define several distinct subgroups. Twenty-three tumors were classified as plasmablastic lymphoma of the oral mucosa type and showed a monomorphic population of immunoblasts with no or minimal plasmacytic differentiation. Most patients were HIV+ and EBV was positive in 74%. Eleven (48%) cases presented in the oral mucosa, but the remaining presented in other extranodal (39%) or nodal (13%) sites. Sixteen cases were classified as plasmablastic lymphoma with plasmacytic differentiation. These were composed predominantly of immunoblasts and plasmablasts, but in addition exhibited more differentiation to mature plasma cells. Only 33% were HIV+, EBV was detected in 62%, and 44% had nodal presentation. Nine cases, morphologically indistinguishable from the previous group, were secondary extramedullary plasmablastic tumors occurring in patients with prior or synchronous plasma cell neoplasms, classified as multiple myeloma in 7 of the 9. Two additional neoplasms were an HHV-8+ extracavitary variant of primary effusion lymphoma and an ALK+ DLBCL. HHV-8 was examined in 39 additional cases, and was negative in all. In conclusion, DLBCLs with plasmablastic differentiation are a heterogeneous group of neoplasms with different clinicopathological characteristics that may correspond to different entities.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.pas.0000126781.87158.e3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spontaneous Regression of Plasmablastic Lymphoma Associated With Methotrexate After Withdrawal.
J Hematol
December 2024
Department of Hematology, Chuno Kosei Hospital, Gifu, Japan.
Plasmablastic lymphoma (PBL) is a malignant lymphoma with poor prognosis that occurs in immunocompromised and elderly patients. We describe the case of a 75-year-old woman with PBL as a methotrexate-associated lymphoproliferative disorder (MTX-LPD). She presented with multiple oral ulcers and mass-like shadows in the lung fields.
View Article and Find Full Text PDFPlasmablastic multiple myeloma presenting as a pleural mass: a diagnostic challenge.
BMJ Case Rep
November 2024
Pathology, Hackensack Meridian Hackensack University Medical Center, Hackensack, New Jersey, USA.
Plasmablastic multiple myeloma (MM) is a rare and highly aggressive variant of MM that presents significant diagnostic and therapeutic challenges. This variant is characterised by a bone marrow infiltration of ≥2% plasmablasts and is distinguished by its atypical pleomorphic morphology, unique immunohistological profile and extensive extramedullary involvement. The anaplastic features of plasmablastic MM can closely mimic those of high-grade lymphomas, leukaemia, non-haematopoietic malignancies and high-grade carcinomas, often leading to initial diagnostic errors.
View Article and Find Full Text PDFAn Update on EBV-related Cutaneous Lymphoproliferative Disorders: a Systematic Review.
Actas Dermosifiliogr
November 2024
Universidad de Zaragoza, Zaragoza, España; Servicio de Anatomía Patológica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
Epstein Barr virus (EBV) positive B lymphoproliferative disorders (LPD) with cutaneous involvement include a series of rare entities that go from indolent processes to aggressive lymphomas. B-cell EBV+ LPD mainly affect immunocompromised patients while T-cell EBV+ LPD are more prevalent in specific geographic regions such as Asia, Central America, and South America. Since the latest WHO-EORTC classification of cutaneous lymphomas in 2018, significant changes have been included in the new classifications of hematological malignancies.
View Article and Find Full Text PDFEpstein-Barr virus-positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature.
Am J Clin Pathol
September 2024
Department of Pathology, Division of Dermatology, Department of Hematology and Hematopoietic Cell Transplantation, and Beckman Research Institute, City of Hope Medical Center, Duarte, CA, US.
Article Synopsis
- Epstein-Barr Virus (EBV) positive primary cutaneous marginal zone lymphoma (PCMZL) is rare and can transform into more aggressive forms, like plasmablastic lymphoma (PBL), which is often fatal.
- The case discussed involves a patient with multifocal PCMZL who experienced a sequence of transformations, eventually leading to disease progression and death, despite various treatments, with genetic mutations similar across lymphomas indicating a common origin.
- A review of 18 cases shows that nearly half of patients with transformed PCMZL succumbed to the disease, particularly those diagnosed with multiple disease sites, highlighting the poor prognosis associated with this transformation.
EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk-stratification, and management.
Am J Hematol
October 2024
Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA.
Article Synopsis
- Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) is a serious type of B-cell lymphoma linked to EBV infection, with prognosis improving due to advancements in chemoimmunotherapy since its inclusion in the WHO classification in 2016.
- Diagnosis relies on detailed pathological evaluation, primarily through detecting EBV-encoded RNA (EBER), with guidelines suggesting that a majority of malignant cells should express EBER for a definitive diagnosis.
- Risk assessment tools like the International Prognostic Index (IPI) and the Oyama score help determine patient outlook, and management typically follows that of EBV-negative DLBCL, although patients may have a worse prognosis, underscoring
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!